AURAAura Biosciences, Inc.

AURA Stock Price, Valuation & Chart | Aura Biosciences, Inc.

Compare

$7.500+0.07 (+0.94%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AURA intrinsic value AURA calculated fair value vs price

Overview Financials Dividends Ratios

AURA Historical price chart

AURA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization775.77M

PE Ratio-4.31

EPS-1.74

Trading Volume495.49K

Today's High/Low7.64/7.0

Dividend Yield0.00

52 Week High/Low9.54/4.73

Shares Outstanding103.44M

AURA Financial Statement

AURA Analyst ratings

AURA Analysis & performance metrics

AURA Company profile

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform…

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology…

AURA Management team

Name

Position

Jill J. Hopkins M.D.

Chief Medical Officer & President of Research and Development

Richard Mountfield Ph.D.

Senior Vice President of Regulatory Affairs & Quality

Elisabet de los Pinos Ph.D.CEO

Founder, Chief Executive Officer, President & Director

Amy ElazzouziCFO

Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer

Mark Plavsic D.V.M., Ph.D.CTO

Chief Technology Officer

Patrick Nealon

Senior Vice President of Clinical Development Operations

Conor Kilroy

Chief Legal Officer & Secretary

Sabine Brookman-May

Senior Vice President & Therapeutic Area Head of Urologic Oncology

Name

Position

Jill J. Hopkins M.D.

Chief Medical Officer & President of Research and Development

Richard Mountfield Ph.D.

Senior Vice President of Regulatory Affairs & Quality

Elisabet de los Pinos Ph.D.CEO

Founder, Chief Executive Officer, President & Director

Amy ElazzouziCFO

Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer

Mark Plavsic D.V.M., Ph.D.CTO

Chief Technology Officer

Patrick Nealon

Senior Vice President of Clinical Development Operations

Conor Kilroy

Chief Legal Officer & Secretary

Sabine Brookman-May

Senior Vice President & Therapeutic Area Head of Urologic Oncology

Management Team

Jill J. Hopkins M.D.

Chief Medical Officer & President of Research and Development

Richard Mountfield Ph.D.

Senior Vice President of Regulatory Affairs & Quality

Elisabet de los Pinos Ph.D.CEO

Founder, Chief Executive Officer, President & Director

Amy ElazzouziCFO

Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer

Mark Plavsic D.V.M., Ph.D.CTO

Chief Technology Officer

Patrick Nealon

Senior Vice President of Clinical Development Operations

Conor Kilroy

Chief Legal Officer & Secretary

Sabine Brookman-May

Senior Vice President & Therapeutic Area Head of Urologic Oncology

Management

Jill J. Hopkins M.D.

Chief Medical Officer & President of Research and Development

Richard Mountfield Ph.D.

Senior Vice President of Regulatory Affairs & Quality

Elisabet de los Pinos Ph.D.CEO

Founder, Chief Executive Officer, President & Director

Amy ElazzouziCFO

Interim Chief Financial Officer, Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer

Mark Plavsic D.V.M., Ph.D.CTO

Chief Technology Officer

Patrick Nealon

Senior Vice President of Clinical Development Operations

Conor Kilroy

Chief Legal Officer & Secretary

Sabine Brookman-May

Senior Vice President & Therapeutic Area Head of Urologic Oncology

Total 8 executives

AURA Frequently asked questions

What is Aura Biosciences, Inc. (AURA) Stock Price?

Current stock price of Aura Biosciences, Inc. (AURA) stock is $7.500. The stock price is +0.94% higher in the session. The intraday range can be seen from this page. Volume of Aura Biosciences, Inc. (AURA) stock is 495.49K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Aura Biosciences, Inc. (AURA) stock price going up or down today?

The stock price of Aura Biosciences, Inc. (AURA) can change with earnings, company news, and overall market sentiment. Aura Biosciences, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Aura Biosciences, Inc. stock expensive at its current price?

Whether Aura Biosciences, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AURA on this page is -4.31. EPS on this page is -1.74. Compare those figures with peers and growth expectations before deciding if the current Aura Biosciences, Inc. price is justified.

How has the stock price of Aura Biosciences, Inc. (AURA) performed historically?

Historical performance for Aura Biosciences, Inc. (AURA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AURA reacted to past earnings and market events.

Should I buy Aura Biosciences, Inc. (AURA) stock, at this price?

Buying Aura Biosciences, Inc. (AURA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.